Business
Volition Signs Co-Marketing and Services Agreement with Hologic
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.","length":306,"tagName":"p"},{"type":"text","content":"The Nu.Q® Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready.","length":247,"tagName":"p"},{"type":"text","content":"Under the agreement, Hologic (NASDAQ: HOLX) will co-market Nu.Q® Discover services of Volition with Hologic Customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further terms being agreed.","length":284,"tagName":"p"},{"type":"text","content":"Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition, said:","length":68,"tagName":"p"},{"type":"text","content":""This is a significant milestone for our Nu.Q® Discover program and will greatly expand customer access to our proprietary Nu.Q® Discover assays, which have an estimated total addressable market of $200 million annually".[1]","length":234,"tagName":"p"},{"type":"text","content":""Hologic has extensive experience, recording revenues of over $4 billion in 2024, from a large client base and international reach, providing tools to biotech and pharma companies and also to academic and government organizations. We have seen strong growth in interest and revenue for our Nu.Q® Discover services and believe this partnership with Hologic will further accelerate the expansion of our Nu.Q® Discover services to a wider base of customers."","length":465,"tagName":"p"},{"type":"text","content":""The inclusion of our nucleosome-based biomarkers in Hologic's portfolio demonstrates a strong validation of their value in clinical development.","length":154,"tagName":"p"},{"type":"text","content":""We look forward to working with the Hologic team as we strengthen our position in the pharmaco-epigenetics market, to help us to grow our revenues."","length":159,"tagName":"p"},{"type":"text","content":"Raphae...